PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is pleased to announce that the Company has qualified to trade on the OTCQX^® Best Market in the United States and secured Depository Trust Company (“DTC”) eligibility. PharmaCielo’s shares were previously traded on the OTC Markets’ Pink^® Market under the ticker “PHCEF” and have begun trading today on the top tier OTCQX^® Best Market under an updated ticker symbol of “PCLOF”.

“Having our shares traded on the top-tier of the OTC Markets in the U.S. is a testament to PharmaCielo’s successful transition from the start-up phase into a mature medicinal cannabis company with robust operating infrastructure,” said David Attard, CEO of PharmaCielo Ltd. “Being traded on the OTCQX Market is expected to provide PharmaCielo with greater visibility for U.S. and international investors who are looking for opportunities to participate in the burgeoning global medical cannabis industry. In addition, DTC eligibility will provide added convenience to U.S. investors, brokers and institutions.”

PharmaCielo’s common shares continue to trade on the TSX Venture Exchange under the symbol TSXV: PCLO.

DTC Eligibility
DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. DTC eligibility enables easier trading and transferring of the Company’s common shares between brokerages in the U.S. Securities that are eligible to be electronically cleared and settled through DTC are considered to be “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for certain investors.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PharmaCielo Ltd.